Want to see SE:DVYSR full AI Analyst Report?

Devyser Diagnostics AB (DVYSR) Price & Analysis

1 Followers

DVYSR Stock Chart & Stats

kr68.20

kr0.40(0.59%)

At close: Jul 29 4:00 PM EDT

kr68.20

kr0.40(0.59%)

Day’s Range― - ―

52-Week Rangekr57.80 - kr159.60

Previous CloseN/A

Volume16.23K

Average Volume (3M)47.37K

Market Cap

kr1.10B

Enterprise Valuekr1.41K

Total Cash (Recent Filing)kr81.00M

Total Debt (Recent Filing)kr45.80M

Price to Earnings (P/E)71.8

Beta0.57

Next Earnings

Nov 03, 2026

EPS Estimate

0.05

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.92

Shares Outstanding16,653,658

10 Day Avg. Volume14,030

30 Day Avg. Volume47,365

Financial Highlights & Ratios

PEG Ratio2.59

Price to Book (P/B)5.35

Price to Sales (P/S)7.56

P/FCF Ratio282.82

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)1.27

Revenue Forecast (FY)kr265.87M

Bulls Say, Bears Say

Bulls Say

Profitability InflectionThe company has moved to TTM profitability with double‑digit operating and strong EBITDA margins, signaling structural operating leverage. Sustained profitability provides cash for reinvestment in commercial scale, R&D and regulatory filings, reducing dependence on financing.

High Gross MarginsApproximately 80% gross margins reflect durable product economics typical of molecular IVD kits, enabling strong incremental margins as volumes scale. High product gross margins support margin sustainability, funding of support services and pricing resilience versus raw material shifts.

Conservative LeverageLow leverage and a sizable equity base give the company financial flexibility to fund commercial expansion, regulatory work and uneven reimbursement cycles. A light debt load reduces interest risk and preserves capacity for targeted M&A or capex if growth opportunities arise.

Bears Say

Weak Revenue TrendTop‑line contraction suggests current earnings improvement is driven more by cost and margin actions than sustainable demand growth. For diagnostics, recurring volume and placements matter; without durable revenue expansion, maintaining margins and improving returns is more difficult long term.

Uneven Cash ConversionFree cash flow has turned positive but converts inconsistently versus reported earnings, implying earnings quality or working‑capital dynamics still under strain. Persistent weak cash conversion would limit self-funded growth, increase execution risk, and constrain reinvestment or dividend capacity.

Modest Returns On EquityReturn on equity remains low for the industry, indicating the company is only beginning to recover profitability. Modest ROE signals that capital is not yet being highly productive, making sustained investor support and capital access contingent on durable top-line improvement.

DVYSR FAQ

What was Devyser Diagnostics AB’s price range in the past 12 months?

Devyser Diagnostics AB lowest stock price was kr57.80 and its highest was kr159.60 in the past 12 months.

What is Devyser Diagnostics AB’s market cap?

Devyser Diagnostics AB’s market cap is kr1.10B.

When is Devyser Diagnostics AB’s upcoming earnings report date?

Devyser Diagnostics AB’s upcoming earnings report date is Nov 03, 2026 which is in 91 days.

How were Devyser Diagnostics AB’s earnings last quarter?

Devyser Diagnostics AB released its earnings results on Jul 20, 2026. The company reported kr0.1 earnings per share for the quarter, missing the consensus estimate of kr0.393 by -kr0.293.

Is Devyser Diagnostics AB overvalued?

According to Wall Street analysts Devyser Diagnostics AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Devyser Diagnostics AB pay dividends?

Devyser Diagnostics AB does not currently pay dividends.

What is Devyser Diagnostics AB’s EPS estimate?

Devyser Diagnostics AB’s EPS estimate is 0.05.

How many shares outstanding does Devyser Diagnostics AB have?

Devyser Diagnostics AB has 16,653,658 shares outstanding.

What happened to Devyser Diagnostics AB’s price movement after its last earnings report?

Devyser Diagnostics AB reported an EPS of kr0.1 in its last earnings report, missing expectations of kr0.393. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Devyser Diagnostics AB?

Currently, no hedge funds are holding shares in SE:DVYSR

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Devyser Diagnostics AB

Headquartered in Hägersten, Sweden, and established in 2004, Devyser Diagnostics AB (publ) specializes in the development, manufacturing, and global sale of advanced diagnostic kits and solutions for DNA testing. The company's innovative products are crucial for genetic analysis in key medical areas, including hereditary diseases, oncology, and post-transplantation monitoring. Devyser offers a broad array of diagnostic tools, covering applications such as post-transplant management, thalassemia screening, and the detection of various cancers like breast, colorectal, and ovarian. Their portfolio also extends to non-invasive fetal RHD screening, diagnostics for inherited conditions, cystic fibrosis, cardiovascular issues, male infertility, and rapid aneuploidy analysis, complemented by essential accessories. These solutions are utilized for diverse purposes, from diagnosing genetic disorders and guiding targeted cancer treatments to ensuring thorough follow-up care for transplant patients. Furthermore, Devyser provides specialized software programs, including Amplicon Suite and Advyser, which facilitate the processing, analysis, and interpretation of test results, enabling efficient marker screening and patient sample tracking. The company's operations span Sweden, the broader European market, the Middle East, Africa, North and South America, and Asia.